MedTrace Logo

Safety Study of NBP608 in Healthy Adult Volunteers

NCT03121638 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-04-20

No results posted yet for this study

Summary

* Indication: Protection against varicella and herpes zoster
* Study Objectives

* Primary: Safety and tolerability assessment after single dose administration of NBP608
* Secondary: immunogenicity assessment after single dose administration of NBP608

Conditions

  • Varicella Zoster
  • Immunization; Infection

Interventions

BIOLOGICAL

VARIVAX

Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

BIOLOGICAL

ZOSTAVAX

Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

BIOLOGICAL

NBP6081

Preparation of Oka/SK strain of live, attenuated varicella zoster virus

BIOLOGICAL

NBP6082

Preparation of Oka/SK strain of live, attenuated varicella zoster virus

BIOLOGICAL

NBP6083

Preparation of Oka/SK strain of live, attenuated varicella zoster virus

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hee-jin Cheong · Korea University Guro Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-02-28
Completion
2013-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03121638 on ClinicalTrials.gov